Surf Wiki
Save to docs
general/heparins

From Surf Wiki (app.surf) — the open knowledge base

Dalteparin sodium

Pharmaceutical drug

Pharmaceutical drug

| Drugs.com =

| elimination_half-life = 3-5 hours subcutaneous; 2.1-2.3 hours IV

Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism and to reduce the risk of a stroke or heart attack. Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin. It is normally administered by self-injection.

The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism (VTE), dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events. Dalteparin is not superior to unfractionated heparin in preventing blood clots.

Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced. Approximately 70% of dalteparin is excreted through kidneys based on animal studies.

In May 2019, the U.S. Food and Drug Administration (FDA) approved Fragmin injection to reduce the recurrence of symptomatic VTE in pediatric patients one month of age and older. It is on the World Health Organization's List of Essential Medicines.

References

References

  1. (27 November 2019). "Dalteparin (Fragmin) Use During Pregnancy".
  2. Dalteparin - Subcutaneous Injection, HealthLinkBC. https://www.healthlinkbc.ca/medications/fdb0271 {{Webarchive. link. (2021-05-03)
  3. Pfizer Medical Information: Fragmin Pharmacodynamics. https://www.pfizermedicalinformation.ca/en-ca/fragmin/action-and-clinical-pharmacology# {{Webarchive. link. (2021-05-07)
  4. (2003). "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med.
  5. The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. (2011). "Dalteparin versus unfractionated heparin in critically ill patients". New England Journal of Medicine.
  6. (2008). "Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin". Arch Intern Med.
  7. Pfizer Medication Information: Fragmin Pharmacokinetics. https://www.pfizermedicalinformation.ca/en-ca/fragmin/action-and-clinical-pharmacology# {{Webarchive. link. (2021-05-07)
  8. "FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots, PM FDA, May 16, 2019". U.S. [[Food and Drug Administration]] (FDA).
  9. (2021). "World Health Organization model list of essential medicines: 22nd list (2021)". World Health Organization.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

heparins drugs-developed-by-pfizer polysaccharides
Want to explore this topic further?

Ask Mako anything about Dalteparin sodium — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report